Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy

• US 7,629,325 B2
• Filed: 07/27/2006
• Issued: 12/08/2009
• Est. Priority Date: 10/11/2004
• Status: Expired due to Fees

• Current Assignee: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD.
• Original Assignee: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD.
• Inventors: Ron, Dina
• Primary Examiner(s): Aeder; Sean E
• Application Number:
  US11/493,608
• Publication Number:
  US 20060293240A1
• Time in Patent Office: 1,230 Days
• Field of Search: 514/44
• US Class Current: 514/44.00R
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/4703 Inhibitors; Suppressors
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 2319/21 containing a His-tag
• CPC Class Codes: C07K 2319/41 containing a Myc-tag

Abstract

A method and pharmaceutical compositions useful for inhibiting the growth of solid tumors (e.g., skin caner) are provided. Specifically, the method is effected by administering to a subject in need thereof an agent capable of upregulating the expression level and/or activity of at least a functional portion of Sef, wherein the functional portion being capable of inhibiting RTK-mediated cell proliferation and whereas upregulating can be effected by: expressing in cells of the subject an exogenous polynucleotide encoding at least a functional portion of Sef (e.g., SEQ ID NOs:4, 8 or 9); increasing expression of endogenous Sef in cells of the subject; increasing endogenous Sef activity in cells of the subject; and introducing an exogenous peptide and/or exogenous polypeptide including at least a functional portion of Sef to the subject. Also provided are methods and kits for diagnosing and staging of cancer (e.g., breast cancer, thyroid cancer, prostate cancer) by detecting the expression level of hSef in a tissue sample, wherein a decrease in hSef expression level is indicative of cancer.

Claims

1. A method of inhibiting a growth of a prostate tumor in a subject, the method comprising intratumorally injecting a nucleic acid construct which comprises the exogenous polynucleotide as set forth by SEQ ID NO:

4 and a promoter capable of directing an expression of said exogenous polynucleotide in cells of said prostate tumor of the subject, thereby inhibiting the growth of the prostate tumor in the subject.

2. The method of claim 1, wherein said promoter is selected from the group consisting of Cytomegalovirus (CMV) promoter, simian virus (SV)-40 early promoter, SV-40 late promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus (RSV) promoter, and polyhedrin promoter.